EditorialPPARG: A New Independent Marker for Colorectal Cancer Survival
References (32)
- et al.
Colorectal cancer expression of PPARG (peroxisome proliferator-activated receptor-gamma) is associated with good prognosis
Gastroenterology
(2009) - et al.
Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms
Trends Immunol
(2007) - et al.
Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor
Cell
(1994) - et al.
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)
J Biol Chem
(1995) - et al.
Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells
Gastroenterology
(1998) - et al.
Genomic and epigenetic instability in colorectal cancer pathogenesis
Gastroenterology
(2008) - et al.
Pathways connecting inflammation and cancer
Curr Opin Genet Dev
(2008) Nuclear hormone receptors and intestinal inflammation
Gastroenterology
(2007)- et al.
PPARgamma in immunity and inflammation: cell types and diseases
Biochim Biophys Acta
(2007) - et al.
Chemotherapeutic drugs induce PPAR-gamma expression and show sequence-specific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancer
Neoplasia
(2008)
Synergy between PPARgamma ligands and platinum-based drugs in cancer
Cancer Cell
(2007)
Cancer facts and figures
(2008)
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms
Nat Rev Cancer
(2004)
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults
N Engl J Med
(2003)
Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta
Proc Natl Acad Sci U S A
(1997)
Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma
Proc Natl Acad Sci U S A
(1997)
Cited by (9)
The Role of the Human Gutome on Chronic Disease: A Review of the Microbiome and Nutrigenomics
2022, Clinics in Laboratory MedicineKnockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells
2016, Journal of Steroid Biochemistry and Molecular BiologyCitation Excerpt :By contrast, our previous studies show elevated AKR1C3 deprives AML cells of J-series prostaglandins that can act as endogenous PPAR ligands. Given that PPARg ligands have been investigated for the treatment of various cancer types for example neuroblastomas [60], colorectal [61], breast and prostate cancers [62,63]. It was hypothesized that the role in CaP for AKR1C3 may be to silence PPAR signaling.
PPARG expression in colorectal cancer and its association with staging and clinical evolution
2020, Acta Cirurgica BrasileiraKey genes and pathways predicted in papillary thyroid carcinoma based on bioinformatics analysis
2016, Journal of Endocrinological Investigation
Conflicts of interest The authors disclose no conflicts.
Copyright © 2009 AGA Institute. Published by Elsevier Inc. All rights reserved.